

Date: 21/04/2017

FREEDOM OF INFORMATION REQUEST FOI/013374 – Biologics & biosimilars

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below.

- **Rheumatoid Arthritis**
- **Ankylosing Spondylitis**
- **Psoriatic Arthritis**

Number of patients treated	Abatacept [Orencia]	Adalimumab [Humira]	Apremilast [Otezla]	Certolizumab [Cinzia]	Etanercept [Enbrel]	Etanercept Biosimilar	Golimumab [Simponi]	Infliximab [Remicade]	Infliximab Biosimilar	Rituximab [Mabthera]	Secukinumab [Cosentyx]	Tocilizumab [Ro Actemra]
Rheumatoid Arthritis												
Ankylosing Spondylitis												
Psoriatic Arthritis												

Response:

All high cost drugs now require pre-approval before these can be prescribed / dispensed.

Most CCGs are using Blueteq <https://www.blueteq-secure.co.uk/trust/Default.aspx> : NHS High Cost / IFR database to ensure Acute providers undertake pre-approval verification of high cost drugs. This database is not locally configurable and as such The Trust is unable to extract reports by drug and indication. Individual CCGs may be able to do this.